Further, to avoid the worsening of disease activity or quality of life following the drug tapering, a close monitoring of these patients should be conducted, i.e., by employing biomarkers of inflammation, such as fecal calprotectin in the case of IBD to predict a disease relapse after anti-TNF-α withdrawal or de-escalation. The gene discussed is TNF; the disease is inflammatory bowel disease.